Biopharmaceutical company focused on precision therapy for genomically defined cancers and rare diseases.
Blueprint Medicines Corporation is a pioneering precision therapy company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for genomically defined cancers and blood disorders on a global scale.
At the forefront of its robust pipeline is AYVAKIT, designed to address systemic mastocytosis (SM) and gastrointestinal stromal tumors, demonstrating the company's commitment to advancing therapies tailored to specific genetic markers. The company is also advancing BLU-263, an orally available potent inhibitor of KIT, targeting non-advanced SM and other mast cell disorders, alongside Fisogatinib, an oral inhibitor aimed at treating hepatocellular carcinoma.
Blueprint Medicines is actively progressing GAVRETO, a treatment for RET fusion-positive non-small cell lung cancer and various solid tumors, showcasing its focus on transformative therapies across different cancer types. The company is also developing BLU-701, BLU-945, and BLU-451 for epidermal growth factor receptor-driven non-small-cell lung carcinoma (NSCLC), with additional efforts directed at therapies like BLU-782 for fibrodysplasia ossificans progressive and BLU-222 for cyclin E aberrant cancers.
Founded in 2008 and initially known as Hoyle Pharmaceuticals, Inc., Blueprint Medicines Corporation rebranded in June 2011, reflecting its strategic evolution in precision medicine. With collaboration and license agreements with industry leaders like Genentech, Roche, and Zai Lab, the company continues to expand its capabilities in developing groundbreaking therapies aimed at addressing critical unmet medical needs in oncology and beyond.